Department of Microbiology, Immunology & Pathology 1692, Colorado State University, Fort Collins, CO 80523, USA.
Virology. 2011 Jun 5;414(2):146-52. doi: 10.1016/j.virol.2011.03.016. Epub 2011 Apr 13.
We recently described a Venezuelan equine encephalitis virus (VEEV)-specific human monoclonal antibody (MAb), F5 nIgG, that recognizes a new neutralization epitope on the VEEV E2 envelope glycoprotein. In this study, we investigated the ability of F5 nIgG given prophylactically or therapeutically to protect mice from subcutaneous or aerosolized VEEV infection. F5 nIgG had potent ability to protect mice from infection by either route when administered 24h before exposure; however, mice treated 24h after aerosol exposure developed central nervous system infections but exhibited no clinical signs of disease. Infectious virus, viral antigen and RNA were detected in brains of both treated and untreated mice 2-6 days after aerosol exposure but were cleared from the brains of treated animals by 14-28 days after infection. This fully human MAb could be useful for prophylaxis or immediate therapy for individuals exposed to VEEV accidentally in the laboratory or during a deliberate release.
我们最近描述了一种委内瑞拉马脑炎病毒（VEEV）特异性人源单克隆抗体（MAb），F5 nIgG，它识别 VEEV E2 包膜糖蛋白上的新中和表位。在这项研究中，我们研究了预防性或治疗性给予 F5 nIgG 以保护小鼠免受皮下或气溶胶 VEEV 感染的能力。F5 nIgG 在暴露前 24 小时给药时具有很强的能力来保护小鼠免受任何途径的感染；然而，气溶胶暴露后 24 小时治疗的小鼠发展为中枢神经系统感染，但没有疾病的临床症状。在气溶胶暴露后 2-6 天，治疗和未治疗的小鼠的大脑中均检测到感染性病毒、病毒抗原和 RNA，但在感染后 14-28 天，治疗动物的大脑中已清除这些物质。这种完全人源化的 MAb 可用于预防或立即治疗在实验室或故意释放过程中意外接触 VEEV 的个体。
